Jeffrey B. Landau - Feb 2, 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role: Chief Business Officer
Signature: /s/ Lloyd Rowland, as Attorney-in-Fact for Jeffrey B Landau
Stock symbol: CTMX
Transactions as of: Feb 2, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/6/2023, 03:49 PM
Previous filing: Aug 12, 2022
Next filing: Mar 20, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTMX	Common Stock	Award	$0	+40K	+130.19%	$0.00	70.7K	Feb 2, 2023	Direct	F1, F2
holding	CTMX	Common Stock						4.5K	Feb 2, 2023	Fidelity Traditional IRA
holding	CTMX	Common Stock						3.18K	Feb 2, 2023	Schwab ROTH IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTMX	Stock Option (Right to Buy)	Award	$0	+100K		$0.00	100K	Feb 2, 2023	Common Stock	100K	$2.59	Direct	F3
transaction	CTMX	Performance Stock Units (PSUs)	Award	$0	+75K		$0.00	75K	Feb 2, 2023	Common Stock	75K		Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date.
F2	Includes 56,274 RSUs.
F3	1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing as a service provider through each such date.
F4	Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.